{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:44:35Z","timestamp":1761864275153},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,23]],"date-time":"2021-04-23T00:00:00Z","timestamp":1619136000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,4,23]],"date-time":"2021-04-23T00:00:00Z","timestamp":1619136000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Immune checkpoint inhibitors have recently become widely used for the management of advanced cancer patients. During the development of immune checkpoint inhibitors (ICPIs), it was quickly recognized that they are associated with autoimmune or autoinflammatory side effects. These toxicities are known as immune-related adverse events (irAEs): common endocrine irAEs include hypophysitis and thyroid dysfunction, and uncommon irAEs include type 1 diabetes mellitus (T1DM).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>A 62-year-old Japanese man with metastatic renal cell carcinoma was treated with sunitinib followed by the 10th cycle of treatment with the ICPI nivolumab. He had already had thyroiditis and hypophysitis due to these anti-cancer drugs. On admission, he showed an extremely elevated plasma glucose level (601\u00a0mg\/dl) and a low C-peptide level, and was diagnosed with acute T1DM. The patient was treated with intravenous fluid infusion and continuous insulin infusion. On the second day, he was switched to multiple daily injections of insulin therapy. Since these treatments, his blood glucose levels have been stable and he has been treated with an additional 10 ICPI treatments for renal cell carcinoma for over a year.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Treatment with ICPIs is expected to increase in the future. There may be cases in which their use for cancer treatment is inevitable despite the side effects. As long as treatment with ICPI continues, multiple side effects can be expected in some cases. It is important to carefully observe the side effects that occur during ICPI treatment and to provide appropriate treatment for each side effect.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13256-020-02656-7","type":"journal-article","created":{"date-parts":[[2021,4,23]],"date-time":"2021-04-23T13:09:19Z","timestamp":1619183359000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Nivolumab-induced hypophysitis followed by acute-onset type 1 diabetes with renal cell carcinoma: a\u00a0case report"],"prefix":"10.1186","volume":"15","author":[{"given":"Fumi","family":"Kikuchi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takanobu","family":"Saheki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitomi","family":"Imachi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihiro","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kensaku","family":"Fukunaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiro","family":"Ibata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seisuke","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natsuki","family":"Ban","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingya","family":"Lyu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salimah","family":"Japar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Murao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,4,23]]},"reference":[{"key":"2656_CR1","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"S Topalian","year":"2012","unstructured":"Topalian S, Hodi F. Safety, activity, and immune correlates of anti\u2013PD-1 antibody in cancer. N Engl J Med. 2012;366:443\u20132454.","journal-title":"N Engl J Med"},{"key":"2656_CR2","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1097\/CCO.0000000000000293","volume":"28","author":"F Torino","year":"2016","unstructured":"Torino F, Corsello SM, Salvatori R. Endocrinological side-effects of immune checkpoint inhibitors. Curr Opin Oncol. 2016;28:278\u201387.","journal-title":"Curr Opin Oncol"},{"key":"2656_CR3","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1111\/cen.13063","volume":"85","author":"MN Joshi","year":"2016","unstructured":"Joshi MN, Whitelaw BC, Palomar MTP, Wu Y, Carroll PV. Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: clinical review. Clin Endocrinol. 2016;85:331\u20139.","journal-title":"Clin Endocrinol"},{"key":"2656_CR4","doi-asserted-by":"publisher","first-page":"e55","DOI":"10.2337\/dc15-0401","volume":"38","author":"J Hughes","year":"2015","unstructured":"Hughes J, Vudattu N, Sznol M, et al. Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy. Diabetes Care. 2015;38:e55\u20137.","journal-title":"Diabetes Care"},{"key":"2656_CR5","doi-asserted-by":"publisher","first-page":"e102110","DOI":"10.1371\/journal.pone.0102110","volume":"9","author":"K Yamamoto","year":"2014","unstructured":"Yamamoto K, Mizumoto A, Nishimura K, et al. Association of toxicity of sorafenib and sunitinib for human keratinocytes with inhibition of signal transduction and activator of transcription 3 (STAT3). PLoS ONE. 2014;9:e102110.","journal-title":"PLoS ONE"},{"key":"2656_CR6","doi-asserted-by":"publisher","first-page":"725410","DOI":"10.1155\/2013\/725410","volume":"2013","author":"H Ahmadieh","year":"2013","unstructured":"Ahmadieh H, Salti I. Tyrosine kinase inhibitors induced thyroid dysfunction: a review of its incidence, pathophysiology, clinical relevance, and treatment. Biomed Res Int. 2013;2013:725410.","journal-title":"Biomed Res Int"},{"key":"2656_CR7","first-page":"320","volume":"11","author":"K Numakura","year":"2019","unstructured":"Numakura K, Horikawa Y, Kamada S, et al. Efficacy of anti-PD-1 antibody nivolumab in Japanese patients with metastatic renal cell carcinoma: a retrospective multicenter analysis. Mol Clin Oncol. 2019;11:320\u20134.","journal-title":"Mol Clin Oncol"},{"key":"2656_CR8","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1007\/s11102-015-0671-4","volume":"19","author":"A Faje","year":"2016","unstructured":"Faje A. Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights. Pituitary. 2016;19:82\u201392.","journal-title":"Pituitary"},{"key":"2656_CR9","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ctrv.2016.02.003","volume":"45","author":"TK Eigentler","year":"2016","unstructured":"Eigentler TK, Hassel JC, Berking C, et al. Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy. Cancer Treat Rev. 2016;45:7\u201318.","journal-title":"Cancer Treat Rev"},{"key":"2656_CR10","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1507\/endocrj.EJ16-0161","volume":"63","author":"Y Okano","year":"2016","unstructured":"Okano Y, Satoh T, Horiguchi K, et al. Nivolumab-induced hypophysitis in a patient with advanced malignant melanoma. Endocr J. 2016;63:905\u201312.","journal-title":"Endocr J"},{"key":"2656_CR11","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/nrclinonc.2016.58","volume":"13","author":"C Boutros","year":"2016","unstructured":"Boutros C, Tarhini A, Routier E, et al. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat Rev Clin Oncol. 2016;13:473\u201386.","journal-title":"Nat Rev Clin Oncol"},{"key":"2656_CR12","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ctrv.2017.06.002","volume":"58","author":"M Sznol","year":"2017","unstructured":"Sznol M, Postow MA, Davies MJ, et al. Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management. Cancer Treat Rev. 2017;58:70\u20136.","journal-title":"Cancer Treat Rev"},{"key":"2656_CR13","doi-asserted-by":"publisher","first-page":"e182","DOI":"10.2337\/dc15-1331","volume":"38","author":"C Gaudy","year":"2015","unstructured":"Gaudy C, Cl\u00e9vy \u0106, Monestier S, et al. Anti-PD1 pembrolizumab can induce exceptional fulminant type 1 diabetes. Diabetes Care. 2015;38:e182\u20133.","journal-title":"Diabetes Care"},{"key":"2656_CR14","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1084\/jem.20022125","volume":"198","author":"MJI Ansari","year":"2003","unstructured":"Ansari MJI, Salama AD, Chitnis T, et al. The Programmed Death-1 (PD-1) Pathway Regulates Autoimmune Diabetes in Nonobese Diabetic (NOD) Mice. J Exp Med. 2003;198:63\u20139.","journal-title":"J Exp Med"},{"key":"2656_CR15","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.2337\/diacare.26.8.2345","volume":"26","author":"IA Imagawa","year":"2003","unstructured":"Imagawa IA, Hanafusa T, Uchigata Y, et al. Fulminant type 1 diabetes: a nationwide survey in Japan. Diabetes Care. 2003;26:2345\u201352.","journal-title":"Diabetes Care"},{"key":"2656_CR16","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s13340-018-0362-2","volume":"10","author":"MY Baden","year":"2019","unstructured":"Baden MY, Imagawa A, Abiru N, et al. Characteristics and clinical course of type 1 diabetes mellitus related to anti-programmed cell death-1 therapy. Diabetol Int. 2019;10:58\u201366.","journal-title":"Diabetol Int"},{"key":"2656_CR17","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1111\/jdi.12119","volume":"5","author":"E Kawasaki","year":"2014","unstructured":"Kawasaki E, Maruyama T, Imagawa A, et al. Diagnostic criteria for acute-onset type 1 diabetes mellitus (2012): Report of the committee of Japan diabetes society on the research of fulminant and acute-onset type 1 diabetes mellitus. J Diabetes Investig. 2014;5:115\u20138.","journal-title":"J Diabetes Investig"},{"key":"2656_CR18","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1111\/jdi.12024","volume":"3","author":"A Imagawa","year":"2012","unstructured":"Imagawa A, Hanafusa T, Awata T, et al. Report of the Committee of the Japan Diabetes Society on the Research of Fulminant and Acute-onset Type 1 Diabetes Mellitus: New diagnostic criteria of fulminant type 1 diabetes mellitus (2012). J Diabetes Investig. 2012;3:536\u20139.","journal-title":"J Diabetes Investig"},{"key":"2656_CR19","doi-asserted-by":"publisher","first-page":"e115","DOI":"10.3747\/co.26.4130","volume":"26","author":"S Sakaguchi","year":"2019","unstructured":"Sakaguchi S, Ashida K, Yano S, et al. A case of nivolumab-induced acute-onset type 1 diabetes mellitus in melanoma. Curr Oncol. 2019;26:e115\u20138.","journal-title":"Curr Oncol"},{"key":"2656_CR20","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1007\/s00125-004-1626-x","volume":"48","author":"A Imagawa","year":"2005","unstructured":"Imagawa A, Hanafusa T, Uchigata Y, et al. Different contribution of class II HLA in fulminant and typical autoimmune type 1 diabetes mellitus. Diabetologia. 2005;48:294\u2013300.","journal-title":"Diabetologia"},{"key":"2656_CR21","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/j.2040-1124.2011.00139.x","volume":"3","author":"C Tsutsumi","year":"2012","unstructured":"Tsutsumi C, Imagawa A, Ikegami H, Makino H, Kobayashi T, Hanafusa T. Class II HLA genotype in fulminant type 1 diabetes: a nationwide survey with reference to glutamic acid decarboxylase antibodies. J Diabetes Investig. 2012;3:62\u20139.","journal-title":"J Diabetes Investig"},{"key":"2656_CR22","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1007\/s11102-018-0880-8","volume":"21","author":"M Sum","year":"2018","unstructured":"Sum M, Garcia FV. Immunotherapy-induced autoimmune diabetes and concomitant hypophysitis. Pituitary. 2018;21:556\u20137.","journal-title":"Pituitary"},{"key":"2656_CR23","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.2169\/internalmedicine.53.2158","volume":"53","author":"K Matoba","year":"2014","unstructured":"Matoba K, Mitsuishi S, Hayashida S, et al. Hypopituitarism possibly due to lymphocytic hypophysitis in a patient with type 1 diabetes. Intern Med. 2014;53:1961\u20134.","journal-title":"Intern Med"},{"key":"2656_CR24","doi-asserted-by":"publisher","first-page":"294","DOI":"10.7861\/clinmedicine.16-3-294","volume":"16","author":"S Pramanik","year":"2016","unstructured":"Pramanik S, Bhattacharjee R, Mukhopadhyay P, et al. Lesson of the month 2: Houssay phenomenon\u2014hypopitutarism leading to remission of diabetes. Clin Med (Lond). 2016;16:294\u20136.","journal-title":"Clin Med (Lond)"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-020-02656-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-020-02656-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-020-02656-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,23]],"date-time":"2021-04-23T13:22:29Z","timestamp":1619184149000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-020-02656-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,23]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2656"],"URL":"https:\/\/doi.org\/10.1186\/s13256-020-02656-7","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,23]]},"assertion":[{"value":"8 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the ethics committees at Kagawa University (ID:2019-268). Written informed consent for publication of this paper was obtained from the patient.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this manuscript and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"214"}}